NCT00715377 is a NA clinical trial of Benztropine in Schizophrenia, sponsored by Centre for Addiction and Mental Health.

Who is sponsoring NCT00715377?

NCT00715377 is sponsored by Centre for Addiction and Mental Health.

What drugs are being tested in NCT00715377?

Interventions in NCT00715377: Benztropine.

What condition does NCT00715377 study?

NCT00715377 studies Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder, Psychotic Disorders.

Is NCT00715377 still recruiting?

NCT00715377 is currently terminated. Last updated 21 August 2015.

Last reviewed 2015-08-21 · How we verify

NCT00715377

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anticholinergic Burden in Schizophrenia

Terminated NA Last updated 21 August 2015

What this trial tests

NA trial testing Benztropine in Schizophrenia in 2 participants. Terminated before completion.

Timeline

1 June 2007

Primary endpoint
1 December 2011

1 December 2011

Quick facts

Lead sponsor	Centre for Addiction and Mental Health
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	1 June 2007
Primary completion	1 December 2011
Estimated completion	1 December 2011
Sites	1 location across Canada

Drugs / interventions tested

Benztropine — full drug profile →

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Schizoaffective Disorder — all drugs for Schizoaffective Disorder →
Schizophreniform Disorder — all drugs for Schizophreniform Disorder →
Delusional Disorder — all drugs for Delusional Disorder →

Sponsor

Centre for Addiction and Mental Health — full company profile →

Who can join

50 and older, any sex, with Schizophrenia or Schizoaffective Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

percentage of participants who successfully withdraw from anticholinergic antiparkinsonian agents.
Time frame: at the end of the study

Sponsor's own description

Anticholinergic antiparkinsonian agents often cause side-effects including cognitive impairment, dry mouth, and constipation while they diminish antipsychotic-induced parkinsonian symptoms. The introduction of second generation antipsychotics (SGA) brought fewer neurological side effects. However, anticholinergic coprescription rates are still as high as 12-65% in patients on SGA that are much higher than the incidence of EPS reported in clinical trials (3-20%). This apparently discrepancy is likely explained, in part, by the established tradition of routine use of this medications. Older patients are particularly sensitive to anticholinergic side-effects due to age-related changes in pharmacokinetics and pharmacodynamics. In this study, we will examine the safety and benefits of reducing the dose of a frequently prescribed anticholinergics, benztropine, on cognitive function, extrapyramidal symptoms, and psychotic symptoms in older subjects with a primary psychotic disorder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Centre for Addiction and Mental Health trials

Trials by the same sponsor.

NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00715377 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
Last refreshed: 21 August 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00715377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing